Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Tetra Bio-Pharma Announces Listing to OTCPink Market PR Newswire MONTREAL, Feb. 10, 2023 MONTREAL, Feb. 10, 2023 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the...
REDUVO™ Marketing Approval on the Right Path PR Newswire MONTREAL, Dec. 22, 2022 Second Clarifax received from Health Canada.MONTREAL, Dec. 22, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc...
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir PR Newswire MONTREAL, Dec. 6, 2022 The combination of ARDS-003 and Favipiravir presents...
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 PR Newswire MONTREAL, Nov. 29, 2022 Tetra strengthens its intellectual property position with PCT and...
Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission PR Newswire MONTREAL, Nov. 18, 2022 MONTREAL, Nov. 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or...
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean PR Newswire OTTAWA, ON, Oct. 27, 2022 OTTAWA, ON, Oct. 27, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc...
Tetra and Prepaire Jointly Apply to BARDA for Funding PR Newswire OTTAWA, ON, Oct. 11, 2022 Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery...
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean PR Newswire OTTAWA, ON, Sept. 8, 2022 OTTAWA, ON, Sept. 8, 2022 /PRNewswire/ - Tetra Bio-Pharma...
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients PR Newswire OTTAWA, ON, Sept. 6, 2022 Tetra and Cellvera to jointly develop an orally...
Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean PR Newswire OTTAWA, ON, Aug. 11, 2022 OTTAWA, ON, Aug. 11, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 156 | -0.135 | -84.375 | 0.16 | 0.18 | 0.015 | 295351 | 0.05951133 | CS |
| 260 | -0.205 | -89.1304347826 | 0.23 | 0.53 | 0.015 | 617706 | 0.20799004 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
